Previous 10 | Next 10 |
Company to Host Investor Webcast at 8:30 a.m. ET on Friday, Sept. 18, 2020 DUBLIN , Sept. 8, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will present new clinical data related to ALKS 4230, its investigational engineered interleukin-2 (IL-2) ...
Entera Bio reports encouraging data from osteoporosis trial Entera Bio Ltd. ( ENTX ) announced interim data from its Phase 2 clinical trial of EB613. The trial is looking to establish the potential of this drug candidate in treating osteoporosis patients. EB613 is an orally delivered hum...
Alkermes plc ( ALKS -1.9% ) is down in early trade, albeit on very light volume, on the heels of the news that an FDA advisory committee will meet on October 9 to review and discuss its marketing application for schizophrenia and bipolar disorder med ALKS 3821. More news on: Alkermes p...
The FDA's Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee will meet virtually on Friday, October 9, to review and discuss Alkermes plc's (NASDAQ: ALKS ) marketing application seeking approval of ALKS 3831 (olanzapine/samidorphan) fo...
DUBLIN , Aug. 21, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that a joint meeting of the U.S. Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to review the New Dr...
Alkermes ( ALKS -0.4% ) announced the initiation of ARTISTRY-3, a new phase 2 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy on the tumor microenvironment in patients with advanced solid tumors. More news on: Alkermes plc, Healthcare stocks news,...
DUBLIN , Aug. 19, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-3, a new phase 2 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy on the tumor microenvironment of a variety of advanced, malignant soli...
DUBLIN , Aug. 17, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the publication of results from the phase 3 ENLIGHTEN-2 clinical trial of ALKS 3831 (olanzapine/samidorphan) in the peer-reviewed publication, American Journal of Psychiatry . ENLIGHTEN-2 was a six-...
Alkermes plc (NASDAQ: ALKS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Alkermes is the commercial-stage company in our coverage that faced some of the most pressure in 1Q20 from the COVID-19 pandemic, as sales of key produc...
Image source: The Motley Fool. Alkermes PLC (NASDAQ: ALKS) Q2 2020 Earnings Call Jul 29, 2020 , 8:00 a.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...